June 24, 2026 - 20:48

Work World, a West Coast specialty retailer focused on workwear and work boots, has appointed Robert Berezansky as its new Chief Financial Officer. The company, which operates as a portfolio firm under Gart Capital Partners, made the announcement on June 24, 2026.
Berezansky brings a background in financial leadership to the role. His experience spans financial planning, capital management, and operational strategy. The company expects him to guide its financial operations as it continues to grow its footprint in the specialty retail sector.
Work World is based in Commerce, California, and has built a reputation as a leading supplier of durable clothing and footwear for tradespeople, construction workers, and other professionals. The retailer serves customers across the West Coast, with a focus on quality and reliability.
The appointment comes as the company looks to strengthen its financial structure and support long-term expansion. Berezansky will oversee budgeting, reporting, and strategic investments. His hiring signals a continued push to refine operations and maintain the brand's position in a competitive market.
September 22, 2026 - 17:57
Finance Committee backs 4-year 1% sales tax continuation; final decision up to Nov. votersCHEYENNE, Wyo. - A four-year continuation of the City of Cheyenne`s optional 1% sales tax is a step closer to appearing on the November ballot after the Finance Committee backed the measure during...
September 22, 2026 - 00:45
Meta stock jumps as Wells Fargo raises price targetMeta shares surged more than 10 percent during trading after Wells Fargo raised its price target on the stock from $640 to $796. The significant bump in the target price reflects growing confidence...
September 21, 2026 - 00:49
LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?LifeMD, Inc. (NASDAQ:LFMD) announced an exclusive healthcare collaboration on September 15 that initially makes virtual-health membership benefits available to approximately 29 million eligible...
September 20, 2026 - 02:49
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA DataXenon Pharmaceuticals saw its stock drop 32.2 percent after the company paused new enrollment in its Phase 3 trials for major depressive disorder and bipolar depression. The decision came on the...